CD133-targeted niche-dependent therapy in cancer: A multipronged approach

American Journal of Pathology

Volumn 184, Issue 5, 2014, Pages 1256-1262

  Mak, Anthony B ^a,b   Schnegg, Caroline ^a   Lai, Chiou Yan ^c   Ghosh, Subrata ^a   Yang, Moon Hee ^a   Moffat, Jason ^b   Hsu, Mei Yu ^a,c  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; GALECTIN 3; GELATINASE A; GELATINASE B; HISTONE DEACETYLASE 6; KALININ; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ANGIOGENESIS; BRAIN CANCER; CANCER STEM CELL; CANCER THERAPY; CUTANEOUS MELANOMA; GENE EXPRESSION; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; STEM CELL NICHE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; VASCULARIZATION;

ANTIGENS, CD; GLYCOPROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES; STEM CELL NICHE;

EID: 84899502069     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.01.008     Document Type: Short Survey

References (51)

1. J.E. Dick Stem cell concepts renew cancer research Blood 112 2008 4793 4807
2. D.M. Park, and J.N. Rich Biology of glioma cancer stem cells Mol Cells 28 2009 7 12
3. + pancreatic cancer stem-like cells Cancer Cell Int 13 2013 119 126
4. G. Ferrandina, M. Petrillo, G. Bonanno, and G. Scambia Targeting CD133 antigen in cancer Expert Opin Ther Targets 13 2009 823 837
5. Y.W. Paulis, P.M. Soetekouw, H.M. Verheul, V.C. Tjan-Heijnen, and A.W. Griffioen Signalling pathways in vasculogenic mimicry Biochim Biophys Acta 1806 2010 18 28
6. K.M. Joo, S.Y. Kim, X. Jin, S.Y. Song, D.S. Kong, J.T. Lee, J.W. Jeon, M.H. Kim, B.G. Kang, Y. Jung, J. Jin, and S.C. Hong Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas Lab Invest 88 2008 808 815
7. J. Wang, P. Sakariassen, O. Tsinkalovsky, H. Immervoll, S.O. Bøe, A. Svendsen, L. Prestegarden, G. Røsland, F. Thorsen, L. Stuhr, A. Molven, R. Bjerkvig, and P.Enger CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells Int J Cancer 122 2008 761 768
8. K. Kemper, M.R. Sprick, B.M. de, A. Scopelliti, L. Vermeulen, M. Hoek, J. Zeilstra, S.T. Pals, H. Mehmet, G. Stassi, and J.P. Medema The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation Cancer Res 70 2010 719 729
9. A.B. Mak, K.M. Blakely, R.A. Williams, P.A. Penttila, A.I. Shukalyuk, K.T. Osman, D. Kasimer, T. Ketela, and J. Moffat CD133 N-glycosylation processing contributes to cell-surface recognition of the primitive cell marker AC133 J Biol Chem 286 2011 41046 41056
10. P. Grosse-Gehling, C.A. Fargeas, C. Dittfeld, Y. Grabe, M.R. Alison, D. Corbeil, and L.A. Kunz-Schughart CD133 as a biomarker for putative cancer stem cells in solid tumors: limitations, problems, and challenges J Pathol 229 2013 355 378
11. E., Irollo, and G. Pirozzi CD133: to be or not to be, is this the real question? Am J Transl Res 5 2013 563 581
12. C.Y. Lai, B.E. Schwartz, and M.Y. Hsu CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry Cancer Res 72 2012 5111 5118
13. A.B. Mak, A.M. Nixon, and J. Moffat The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription Cancer Res 72 2012 1929 1934
14. G. Rappa, O. Fodstad, and A. Lorico The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma Stem Cells 26 2008 3008 3017
15. A. Adini, I. Adini, K. Ghosh, O. Benny, E. Pravda, R. Hu, D. Luyindula, and R.J. D'Amato The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action Angiogenesis 16 2013 405 416
16. T.J. Liu, B.C. Sun, X.L. Zhao, X.M. Zhao, T. Sun, Q. Gu, Z. Yao, X.Y. Dong, N. Zhao, and N. Liu CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer Oncogene 32 2013 544 553
17. M.T. Chiao, Y.C. Yang, W.Y. Cheng, C.C. Shen, and J.L. Ko CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo Curr Neurovasc Res 8 2011 210 219
18. C. Calabrese, H. Poppleton, M. Kocak, T.L. Hogg, C. Fuller, B. Hamner, E.Y. Oh, M.W. Gaber, D. Finklestein, M. Allen, A. Frank, I.T. Bayazitov, S.S. Zakharenko, A. Gajjar, A. Davidoff, and R.J. Gilbertson A perivascular niche for brain tumor stem cells Cancer Cell 11 2007 69 82
19. A.J. Maniotis, R. Folberg, A. Hess, E.A. Seftor, L.M. Gardner, J. Pe'er, J.M. Trent, P.S. Meltzer, and M.J. Hendrix Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry Am J Pathol 155 1999 739 752
20. B. Dome, M.J. Hendrix, S. Paku, J. Tovari, and J. Timar Alternative vascularization mechanisms in cancer: pathology and therapeutic implications Am J Pathol 170 2007 1 15
21. M.J. Hendrix, E.A. Seftor, P.S. Meltzer, L.M. Gardner, A.R. Hess, D.A. Kirschmann, G.C. Schatteman, and R.E. Seftor Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry Proc Natl Acad Sci U S A 98 2001 8018 8023
22. W. Ruf, E.A. Seftor, R.J. Petrovan, R.M. Weiss, L.M. Gruman, N.V. Margaryan, R.E. Seftor, Y. Miyagi, and M.J. Hendrix Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry Cancer Res 63 2003 5381 5389
23. R. Folberg, M.J. Hendrix, and A.J. Maniotis Vasculogenic mimicry and tumor angiogenesis Am J Pathol 156 2000 361 381
24. N. Sharma, R.E. Seftor, E.A. Seftor, L.M. Gruman, P.M. Heidger Jr., M.B. Cohen, D.M. Lubaroff, and M.J. Hendrix Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry Prostate 50 2002 189 201
25. K. Shirakawa, H. Wakasugi, Y. Heike, I. Watanabe, S. Yamada, K. Saito, and F. Konishi Vasculogenic mimicry and pseudo-comedo formation in breast cancer Int J Cancer 99 2002 821 828
26. A.K. Sood, E.A. Seftor, M.S. Fletcher, L.M. Gardner, P.M. Heidger, R.E. Buller, R.E. Seftor, and M.J. Hendrix Molecular determinants of ovarian cancer plasticity Am J Pathol 158 2001 1279 1288
27. D.W. van der Schaft, F. Hillen, P. Pauwels, D.A. Kirschmann, K. Castermans, M.G. Egbrink, M.G. Tran, R. Sciot, E. Hauben, P.C. Hogendoorn, O. Delattre, P.H. Maxwell, M.J. Hendrix, and A.W. Griffioen Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia Cancer Res 65 2005 11520 11528
28. A.Y. Lin, A.J. Maniotis, K. Valyi-Nagy, D. Majumdar, S. Setty, S. Kadkol, L. Leach, J. Pe'er, and R. Folberg Distinguishing fibrovascular septa from vasculogenic mimicry patterns Arch Pathol Lab Med 129 2005 884 892
29. M.J. Hendrix, E.A. Seftor, A.R. Hess, and R.E. Seftor Molecular plasticity of human melanoma cells Oncogene 22 2003 3070 3075
30. A.B. Mak, A.M. Nixon, S. Kittanakom, J.M. Stewart, G.I. Chen, J. Curak, A.C. Gingras, R. Mazitschek, B.G. Neel, I. Stagljar, and J. Moffat Regulation of CD133 by HDAC6 promotes beta-catenin signaling to suppress cancer cell differentiation Cell Rep 2 2012 951 963
31. L.M. Postovit, E.A. Seftor, R.E. Seftor, and M.J. Hendrix Influence of the microenvironment on melanoma cell fate determination and phenotype Cancer Res 66 2006 7833 7836
32. R.E. Seftor, E.A. Seftor, N. Koshikawa, P.S. Meltzer, L.M. Gardner, M. Bilban, W.G. Stetler-Stevenson, V. Quaranta, and M.J. Hendrix Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma Cancer Res 61 2001 6322 6327
33. R.E. Seftor, E.A. Seftor, D.A. Kirschmann, and M.J. Hendrix Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry Mol Cancer Ther 1 2002 1173 1179
34. Y. Chen, Z. Jing, C. Luo, M. Zhuang, J. Xia, Z. Chen, and Y. Wang Vasculogenic mimicry:potential target for glioblastoma therapy: an in vitro and in vivo study Med Oncol 29 2012 324 331
35. J. Mei, Y. Gao, L. Zhang, X. Cai, Z. Qian, H. Huang, and W. Huang VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro Exp Oncol 30 2008 29 34
36. A.A. Mourad-Zeidan, V.O. Melnikova, H. Wang, A. Raz, and M. Bar-Eli Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry Am J Pathol 173 2008 1839 1852
37. R.E. Seftor, A.R. Hess, E.A. Seftor, D.A. Kirschmann, K.M. Hardy, N.V. Margaryan, and M.J. Hendrix Tumor cell vasculogenic mimicry: from controversy to therapeutic promise Am J Pathol 181 2012 1115 1125
38. A.P. Kusumbe, A.M. Mali, and S.A. Bapat CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature Stem Cells 27 2009 498 508
39. X.T. Sun, X.W. Yuan, H.T. Zhu, Z.M. Deng, D.C. Yu, X. Zhou, and Y.T. Ding Endothelial precursor cells promote angiogenesis in hepatocellular carcinoma World J Gastroenterol 18 2012 4925 4933
40. D. Yu, X. Sun, Y. Qiu, J. Zhou, Y. Wu, L. Zhuang, J. Chen, and Y. Ding Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma Clin Cancer Res 13 2007 3814 3824
41. P. Hamerlik, J.D. Lathia, R. Rasmussen, Q. Wu, J. Bartkova, M. Lee, P. Moudry, J. Bartek Jr., W. Fischer, J. Lukas, J.N. Rich, and J. Bartek Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth J Exp Med 209 2012 507 520
42. C. Gu, N. Yokota, Y. Gao, J. Yamamoto, T. Tokuyama, and H. Namba Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells Oncol Lett 2 2011 357 361
43. B. Beck, G. Driessens, S. Goossens, K.K. Youssef, A. Kuchnio, A. Caauwe, P.A. Sotiropoulou, S. Loges, G. Lapouge, A. Candi, G. Mascre, B. Drogat, S. Dekoninck, J.J. Haigh, P. Carmeliet, and C. Blanpain A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours Nature 478 2011 399 403
44. S.A. Choi, K.C. Wang, J.H. Phi, J.Y. Lee, C.K. Park, S.H. Park, and S.K. Kim A distinct subpopulation within CD133 positive brain tumor cells shares characteristics with endothelial progenitor cells Cancer Lett 324 2012 221 230
45. L. Ricci-Vitiani, R. Pallini, M. Biffoni, M. Todaro, G. Invernici, T. Cenci, G. Maira, E.A. Parati, G. Stassi, L.M. Larocca, and M.R. De Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells Nature 468 2010 824 828
46. R. Wang, K. Chadalavada, J. Wilshire, U. Kowalik, K.E. Hovinga, A. Geber, B. Fligelman, M. Leversha, C. Brennan, and V. Tabar Glioblastoma stem-like cells give rise to tumour endothelium Nature 468 2010 829 833
47. S. Bao, Q. Wu, S. Sathornsumetee, Y. Hao, Z. Li, A.B. Hjelmeland, Q. Shi, R.E. McLendon, D.D. Bigner, and J.N. Rich Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res 66 2006 7843 7848
48. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
49. J.J. Verhoeff, T.O. van, A. Claes, L.J. Stalpers, M.E. van Linde, D.J. Richel, W.P. Leenders, and W.R. van Furth Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme BMC Cancer 9 2009 444
50. D.W. van der Schaft, R.E. Seftor, E.A. Seftor, A.R. Hess, L.M. Gruman, D.A. Kirschmann, Y. Yokoyama, A.W. Griffioen, and M.J. Hendrix Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells J Natl Cancer Inst 96 2004 1473 1477
51. Y. Zhang, S. Kwon, T. Yamaguchi, F. Cubizolles, S. Rousseaux, M. Kneissel, C. Cao, N. Li, H.L. Cheng, K. Chua, D. Lombard, A. Mizeracki, G. Matthias, F.W. Alt, S. Khochbin, and P. Matthias Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally Mol Cell Biol 28 2008 1688 1701